Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
In a bear market it’s the bad news that matters
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Despair engulfs smaller device companies
The nightmare on the public markets is not confined to the bigger groups.
Big medtech's share price bloodbath
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
